Any current/future new fundraising through debt or equity?

All capacity expansions are fully funded through incremental borrowings from domestic and international banking relationships. The company has lowered its overall cost of borrowing to below 9%, down by 210 basis points compared to the prior year. No mention of current or planned equity fundraising in the disclosed call; focus is on debt-funded capacity expansion. Management indicated potential inorganic elements for growth beyond the $400 million target but did not specify fundraising modes. No announced new equity issuance; emphasis remains on organic growth and existing funding channels for

Any current/future capex/capital investment/strategic investment?

The company is heavily investing in capacity expansion, particularly in the injectable (DDC) and soft gelatine segments to support future growth. A fourth injectable line is being introduced in Unit 2, featuring advanced capabilities like handling high viscosity pre-filled syringes. Two additional injectable lines are planned for installation within the year, with three lines expected to be operational by end of FY27. Capacity expansion also includes upgrading batch sizes from 200 liters to up to 750–1,000 liters, increasing output by 2.5x. The capex for these expansions is fully funded throug

Future growth expectations in sales/revenue/volumes?

OneSource expects strong growth in FY27 and FY28, with meaningful revenue contributions starting FY27 and commercial biologics manufacturing beginning FY29. The company reiterated its FY28 guidance of US$400 million revenue and 40% EBITDA margin. Expansion of injectable and soft gel capacities, including three DDC lines by end of FY27, will drive sequential quarter-on-quarter revenue and EBITDA improvement. Demand-supply gap expected to persist for at least the next 2 years, with high customer demand and capacity reservations from clients. Biologics business shows strong funnel with ag

Future growth expectations in earnings/operating earnings/profits/EPS?

OneSource expects meaningful contribution from biologics business starting FY27 and FY28, with commercial manufacturing set to begin post-FY28, likely FY29 onwards. FY28 revenue guidance is reaffirmed at US$400 million with an EBITDA margin of around 40%. Sequential quarterly revenue and EBITDA improvements are expected due to new capacity coming online, including two additional DDC (drug device combination) lines by end of FY27. Capacity expansions in soft gels and injectables will drive growth and utilization, with soft gel capacity fully utilized by end of this year or early next year

Current/ Expected Orderbook/ Pending Orders?

The company is fully committed to its current capacity, with strong visibility of robust demand across markets where approvals exist or are expected. Customers have secured capacity reservations through upfront fees and take-or-pay contracts, indicating a firm orderbook on capacity. Demand-supply gap expected to persist for at least the next two years, reflecting strong pending orders and order pipeline. New manufacturing lines (two additional lines scheduled this year and another next year) are being added to meet this demand. Capacity expansions underway in commercial manufacturing, particul

IN US

Sale is live|00:00:00left today

OneSource Specialty Pharma LtdQ1 FY26Pharmaceuticals & Biotechnology

OneSource Specialty Pharma Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,568Market Cap: ₹21.0K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→OneSource expects strong growth in FY27 and FY28, with meaningful revenue contributions starting FY27 and commercial biologics manufacturing beginning FY29.
→The company reiterated its FY28 guidance of US$400 million revenue and 40% EBITDA margin.
→Expansion of injectable and soft gel capacities, including three DDC lines by end of FY27, will drive sequential quarter-on-quarter revenue and EBITDA improvement.
→Demand-supply gap expected to persist for at least the next 2 years, with high customer demand and capacity reservations from clients.
→Biologics business shows strong funnel with agreements expected in FY27 and meaningful contributions in FY28, indicating a long runway for growth.
→Growing markets like Brazil, Saudi Arabia, and Turkey, along with emerging markets, offer significant untapped revenue opportunities.
→Soft gel capacity expected to be fully utilized by end of the current year, with further expansions planned subsequently.

Margin guidance

Category 1

→OneSource expects meaningful contribution from biologics business starting FY27 and FY28, with commercial manufacturing set to begin post-FY28, likely FY29 onwards.
→FY28 revenue guidance is reaffirmed at US$400 million with an EBITDA margin of around 40%.
→Sequential quarterly revenue and EBITDA improvements are expected due to new capacity coming online, including two additional DDC (drug device combination) lines by end of FY27.
→Capacity expansions in soft gels and injectables will drive growth and utilization, with soft gel capacity fully utilized by end of this year or early next year.
→EBITDA in Q4 FY26 showed strong operating leverage with margins expanding 1,550 basis points QoQ.
→FY26 adjusted PAT was INR739 million with a full year EPS of INR6.5; FY27 and beyond expected to show scaling profits and operating leverage.
→The long-term target includes a 50%+ ROCE medium term, indicating strong future profitability.

3 more insights locked — sign up free to unlock

Fundraise plans

→All capacity expansions are fully funded through incremental borrowings from domestic and international banking relationships.
→The company has lowered its overall cost of borrowing to below 9%, down by 210 basis points compared to the prior year.
→No mention of current or planned equity fundraising in the disclosed call; focus is on debt-funded capacity expansion.
→Management indicated potential inorganic elements for growth beyond the $400 million target but did not specify fundraising modes.
→No announced new equity issuance; emphasis remains on organic growth and existing funding channels for expansion.

Order book

→The company is fully committed to its current capacity, with strong visibility of robust demand across markets where approvals exist or are expected.
→Customers have secured capacity reservations through upfront fees and take-or-pay contracts, indicating a firm orderbook on capacity.
→Demand-supply gap expected to persist for at least the next two years, reflecting strong pending orders and order pipeline.
→New manufacturing lines (two additional lines scheduled this year and another next year) are being added to meet this demand.
→Capacity expansions underway in commercial manufacturing, particularly injectable lines, expected to start contributing beyond FY28.
→On Semaglutide and GLP products, demand from multiple global generic and regional partners is strong but specific break-up of orders is confidential.
→Overall, orderbook and pending orders are stable and growing with increasing capacity utilization anticipated by end of current fiscal year.

Capex plans

Yes

→The company is heavily investing in capacity expansion, particularly in the injectable (DDC) and soft gelatine segments to support future growth.
→A fourth injectable line is being introduced in Unit 2, featuring advanced capabilities like handling high viscosity pre-filled syringes.
→Two additional injectable lines are planned for installation within the year, with three lines expected to be operational by end of FY27.
→Capacity expansion also includes upgrading batch sizes from 200 liters to up to 750–1,000 liters, increasing output by 2.5x.
→The capex for these expansions is fully funded through incremental domestic and international borrowings.
→Earlier plans for related party transactions involving Steriscience and Brooks have been deferred, with a potential revisit in around two years.
→The capital investments aim to scale towards the company's $400 million revenue target by FY28 and beyond.

How does OneSource Specialty Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1OneSource Specialty Pharma Ltd

Rev 2Mar 1

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like OneSource Specialty Pharma Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio